Sugi Predict

Sugi Predict / Compounds / SCHEMBL29476617

SCHEMBL29476617

SCHEMBL29476617

N=C(N)NCCC[C@H](NC(=O)[C@@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](N)CS)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MC4R P32245 5/20 0.50
▸ C5AR1 P21730 1/20 0.50
▸ GHSR Q92847 1/20 0.48
▸ KISS1R Q969F8 2/20 0.47
▸ TUBB4A P04350 1/20 0.47
▸ TUBB P07437 1/20 0.47
▸ TUBA3C P0DPH7 1/20 0.47
▸ TUBA1B P68363 1/20 0.47
▸ TUBA4A P68366 1/20 0.47
▸ TUBB4B P68371 1/20 0.47
▸ TUBB3 Q13509 1/20 0.47
▸ TUBB2A Q13885 1/20 0.47
▸ TUBB8 Q3ZCM7 1/20 0.47
▸ TUBA3E Q6PEY2 1/20 0.47
▸ TUBA1A Q71U36 1/20 0.47
▸ TUBA1C Q9BQE3 1/20 0.47
▸ TUBB6 Q9BUF5 1/20 0.47
▸ TUBB2B Q9BVA1 1/20 0.47
▸ TUBB1 Q9H4B7 1/20 0.47
▸ NPY1R P25929 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29476562 1.00 MC4R (0.50) MC4RC5AR1GHSRKISS1RTUBB4A
SCHEMBL29511047 0.98 C5AR1 (0.50) MC4RC5AR1GHSRTUBB4ATUBB
SCHEMBL29476494 0.96 TUBB4A (0.52) MC4RC5AR1GHSRKISS1RTUBB4A
SCHEMBL30510423 0.96 TUBB4A (0.52) MC4RC5AR1GHSRKISS1RTUBB4A
SCHEMBL30080575 0.95 C5AR1 (0.51) MC4RC5AR1KISS1R
SCHEMBL31555126 0.95 MC4R (0.49) MC4RC5AR1GHSRKISS1RTUBB4A
SCHEMBL30725663 0.95 MC4R (0.49) MC4RC5AR1GHSRKISS1RTUBB4A
SCHEMBL30104393 0.95 CTSL (0.47) MC4RC5AR1
SCHEMBL30264960 0.95 CTSL (0.49) MC4RC5AR1KISS1RTUBB4ATUBB
SCHEMBL29511006 0.95 C5AR1 (0.52) MC4RC5AR1KISS1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260085092-A1 MELANOCORTIN RECEPTOR LIGANDS IPSEN PHARMA SAS (FR) 2026-03-26 — — US claimed
US-20260001915-A1 METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST RHYTHM PHARMACEUTICALS INC (US) 2026-01-01 — — US claimed
CN-120152725-A Methods of treating obesity using MC4R agonists 节奏制药公司 2025-06-13 — — CN claimed
EP-4554607-A2 METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST Rhythm Pharmaceuticals, Inc. (US) 2025-05-21 — — EP claimed
WO-2024015880-A2 METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST RHYTHM PHARMACEUTICALS, INC. (US) 2024-01-18 — — WO claimed
US-20220339239-A1 USE OF MELANOCORTINS TO TREAT INSULIN SENSITIVITY IPSEN PHARMA SAS (FR) 2022-10-27 — — US claimed
US-20220127305-A1 MELANOCORTIN RECEPTOR LIGANDS IPSEN PHARMA SAS (FR) 2022-04-28 — — US claimed
US-20260085092-A1 MELANOCORTIN RECEPTOR LIGANDS IPSEN PHARMA SAS (FR) 2026-03-26 — — US disclosed
EP-4711004-A2 METHOD OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS Rhythm Pharmaceuticals, Inc. (US) 2026-03-18 — — EP disclosed
US-20260001915-A1 METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST RHYTHM PHARMACEUTICALS INC (US) 2026-01-01 — — US disclosed
EP-4618952-A2 METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST Rhythm Pharmaceuticals, Inc. (US) 2025-09-24 — — EP disclosed
US-20250195606-A1 METHOD OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS CHARITÉ - UNIVERSITÄTSMEDIZIN BERLIN (DE) 2025-06-19 — — US disclosed
CN-120152725-A Methods of treating obesity using MC4R agonists 节奏制药公司 2025-06-13 — — CN disclosed
EP-4216979-A1 METHODS OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS Rhythm Pharmaceuticals, Inc. (US) 2023-08-02 — — EP disclosed
CN-116507353-A Methods of treating melanocortin-4 receptor pathway-related disorders 节奏制药公司 2023-07-28 — — CN disclosed
US-20220339239-A1 USE OF MELANOCORTINS TO TREAT INSULIN SENSITIVITY IPSEN PHARMA SAS (FR) 2022-10-27 — — US disclosed
EP-4029513-A1 MELANOCORTIN-4 RECEPTOR AGONISTS FOR THE TREATMENT OF DISORDERS CHARACTERISED BY POMC GENE HYPERMETHYLATION Rhythm Pharmaceuticals, Inc. (US) 2022-07-20 — — EP disclosed
US-20220127305-A1 MELANOCORTIN RECEPTOR LIGANDS IPSEN PHARMA SAS (FR) 2022-04-28 — — US disclosed
EP-3988108-A1 METHOD OF TREATING MELANOCORTIN-4 RECEPTOR-ASSOCIATED DISORDERS IN HETEROZYGOUS CARRIERS Rhythm Pharmaceuticals, Inc. (US) 2022-04-27 — — EP disclosed
WO-2022067086-A1 METHODS OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS RHYTHM PHARMACEUTICALS, INC. (US) 2022-03-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260001915-A1 METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST MC4R, NPY4R, MC3R MC4R 1/4885C5AR1 2625/4885GHSR 15/4885
US-20260085092-A1 MELANOCORTIN RECEPTOR LIGANDS THRB, MC1R, MC5R MC4R 8/4885C5AR1 1092/4885GHSR 190/4885
US-20220339239-A1 USE OF MELANOCORTINS TO TREAT INSULIN SENSITIVITY MC4R, MC1R, MC3R MC4R 1/4885C5AR1 607/4885GHSR 33/4885
US-20250195606-A1 METHOD OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS MC4R, MC5R, MC3R MC4R 1/4885C5AR1 2939/4885GHSR 35/4885
US-20220127305-A1 MELANOCORTIN RECEPTOR LIGANDS MC3R, MC1R, MC5R MC4R 4/4885C5AR1 72/4885GHSR 106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback